The Trump administration is launching a new effort to bolster domestic clinical trials for new pharmaceutical products after a year of tumult at the federal health agencies that has slowed down new product approvals and frustrated drugmakers.

Health and Human Services Secretary Robert F. Kennedy Jr. said in a press release that the project, called Operation Trial Blazer, is meant to “restore America’s leadership in clinical research, remove unnecessary barriers, and bring more clinical research and investment back to the United States.”